Illumina Reports the Acquisition of Fluent BioSciences to Expand its Multiomics Portfolio


Illumina has acquired Fluent BioSciences with cash on hand to expand its multiomics portfolio and enhance single-cell analysis & discovery. The financial terms were undisclosed and the acquisition was completed on Jul 9, 2024
The acquisition adds Fluent’s PIPseq V, which can identify cell types missed by conventional methods with the ability to process 100 to 1 million cells showing high scalability, to Illumina’s portfolio
Illumina’s sequencing & informatics technology, Partek Flow, will be integrated with Fluent’s technology to offer a complete single-cell multiomic analysis solution, minimizing the need for complex instruments & consumables, making single-cell analysis more accessible & cost-effective

Ref: Illumina | Image: Illumina

Related News:- Veracyte Signs a Multi-Year Agreement with Illumina to Enhance its IVD Test for the Patients Globally

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at